Juha Rinne

Prof. Dr. Juha Rinne


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in The Lancet Neurology
Verified
Journal Article
Closed access
JRJuha Rinne
Juha Rinne
DBDavid Brooks
David Brooks
MRMartin N Rossor
Martin N Rossor
NFNick C Fox
Nick C Fox
RBRoger Bullock
Roger Bullock
MGMichael Grundman
Michael Grundman

24 April 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CMCatherine J. Mummery
Catherine J. Mummery
ABAnne Börjesson-Hanson
Anne Börjesson-Hanson
DBDaniel J. Blackburn
Daniel J. Blackburn
EVEverard G. B. Vijverberg
Everard G. B. Vijverberg
PDPeter Paul De Deyn
Peter Paul De Deyn
RLRoger M. Lane
Roger M. Lane
Tau plays a key role in Alzheimer’s disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting antisense oligonucleotide (MAPTRx) and reduce tau levels in patients with mild AD. A randomized, double-blind, placebo-controlled, multiple-ascending dose phase 1b trial evaluated the safety, pharmacokinetics and target engagement of MAPTRx. Four ascending dose cohorts were enrolled sequentially and randomized 3:1 to intrathecal bolus administrations of MAPTRx or placebo every 4 or 12 weeks during the 13-week treatment period, followed by a 23 week post-treatment period. The primary endpoint was safety. The secondary endpoint was MAPTRx pharmacokinetics in cerebrospinal fluid (CSF). The prespecified key exploratory outcome was CSF total-tau protein concentration. Forty-six patients enrolled in the trial, of whom 34 were randomized to MAPTRx and 12 to placebo. Adverse events were reported in 94% of MAPTRx-treated patients and 75% of placebo-treated patients; all were mild or moderate. No serious adverse events were reported in MAPTRx-treated patients. Dose-dependent reduction in the CSF total-tau concentration was observed with greater than 50% mean reduction from baseline at 24 weeks post-last dose in the 60 mg (four doses) and 115 mg (two doses) MAPTRx groups. Clinicaltrials.gov registration number: NCT03186989.

12 May 2016 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
RVRik Vandenberghe
Rik Vandenberghe
JRJuha Rinne
Juha Rinne
MBMerce Boada
Merce Boada
SKSadao Katayama
Sadao Katayama
PSPhilip Scheltens
Philip Scheltens
RBRonald S. Black
Ronald S. Black
Background: Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD). Methods: Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted globally: one in apolipoprotein E ε4 carriers and another in noncarriers. Patients received bapineuzumab 0.5 mg/kg (both trials) or 1.0 mg/kg (noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change from baseline to week 78 on the 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale and the Disability Assessment for Dementia. Results: A total of 683 and 329 patients completed the current carrier and noncarrier trials, respectively, which were terminated prematurely owing to lack of efficacy in the two other phase 3 trials of bapineuzumab in AD. The current trials showed no significant difference between bapineuzumab and placebo for the coprimary endpoints and no effect of bapineuzumab on amyloid load or cerebrospinal fluid phosphorylated tau. (Both measures were stable over time in the placebo group.) Amyloid-related imaging abnormalities with edema or effusion were confirmed as the most notable adverse event. Conclusions: These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed. Trial registration: Noncarriers (3000) ClinicalTrials.gov identifier NCT00667810; registered 24 Apr 2008. Carriers (3001) ClinicalTrials.gov identifier NCT00676143; registered 2 May 2008.

19 November 2007 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
NKNina M. Kemppainen
Nina M. Kemppainen
SASargo Aalto
Sargo Aalto
MKMira Karrasch
Mira Karrasch
KNKjell Någren
Kjell Någren
NSNina Savisto
Nina Savisto
JRJuha Rinne
Juha Rinne

1 November 2008 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
JRJuha Rinne
Juha Rinne
SMShuang Yong Ma
Shuang Yong Ma
MLMyung Sik Lee
Myung Sik Lee
YCYrjö Collan
Yrjö Collan
MRMatias Röyttä
Matias Röyttä

4 June 2019 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
FGfor the FINGER study group
for the FINGER study group
RSRuth Stephen
Ruth Stephen
YLYawu Liu
Yawu Liu
TNTiia Ngandu
Tiia Ngandu
RARiitta Antikainen
Riitta Antikainen
ASAlina Solomon
Alina Solomon
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a multicenter randomized controlled trial that reported beneficial effects on cognition for a 2-year multimodal intervention (diet, exercise, cognitive training, vascular risk monitoring) versus control (general health advice). This study reports exploratory analyses of brain MRI measures. FINGER targeted 1260 older individuals from the general Finnish population. Participants were 60–77 years old, at increased risk for dementia but without dementia/substantial cognitive impairment. Brain MRI scans were available for 132 participants (68 intervention, 64 control) at baseline and 112 participants (59 intervention, 53 control) at 2 years. MRI measures included regional brain volumes, cortical thickness, and white matter lesion (WML) volume. Cognition was assessed at baseline and 1- and 2-year visits using a comprehensive neuropsychological test battery. We investigated the (1) differences between the intervention and control groups in change in MRI outcomes (FreeSurfer 5.3) and (2) post hoc sub-group analyses of intervention effects on cognition in participants with more versus less pronounced structural brain changes at baseline (mixed-effects regression models, Stata 12). No significant differences between the intervention and control groups were found on the changes in MRI measures. Beneficial intervention effects on processing speed were more pronounced in individuals with higher baseline cortical thickness in Alzheimer’s disease signature areas (composite measure of entorhinal, inferior and middle temporal, and fusiform regions). The randomization group × time × cortical thickness interaction coefficient was 0.198 (p = 0.021). A similar trend was observed for higher hippocampal volume (group × time × hippocampus volume interaction coefficient 0.1149, p = 0.085). The FINGER MRI exploratory sub-study did not show significant differences between the intervention and control groups on changes in regional brain volumes, regional cortical thicknesses, or WML volume after 2 years in at-risk elderly without substantial impairment. The cognitive benefits on processing speed of the FINGER intervention may be more pronounced in individuals with fewer structural brain changes on MRI at baseline. This suggests that preventive strategies may be more effective if started early, before the occurrence of more pronounced structural brain changes. ClinicalTrials.gov, NCT01041989 . Registered January 5, 2010.